Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion-Reference-Cited by-同舟云学术

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion

Published:2019-07-01 Issue:7 Volume:5 Page:953
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

He MinKe¹,Li QiJiong¹,Zou RuHai²,Shen JingXian³,Fang WanQiang⁴,Tan GuoSheng⁵,Zhou YuanMin⁶,Wu XiaoPing⁷,Xu Li¹,Wei Wei¹,Le Yong¹,Zhou ZhongGuo¹,Zhao Ming⁸,Guo Ying⁹,Guo RongPing¹,Chen MinShan¹,Shi Ming¹

Affiliation:

1. Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

2. Department of Ultrasonography, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

3. Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

4. Kaiping Central Hospital, KaiPing, China

5. First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

6. Guangzhou No.12 People's Hospital, Guangzhou, China

7. The First Affiliated Hospital of the University of South China, HengYang, China

8. Minimally Invasive Interventional Division, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

9. Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/7/953/17712449/jamaoncology_he_2019_oi_190012.pdf

Reference37 articles.

1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease study.;Fitzmaurice;JAMA Oncol,2017

2. Management of hepatocellular carcinoma: an update.;Bruix;Hepatology,2011

3. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.;European Association For The Study Of The Liver;J Hepatol,2012

4. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.;Verslype;Ann Oncol,2012

5. International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study.;Chan;Chin J Cancer,2014

Cited by 279 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitiors for unresectable hepatocellular carcinoma and meta-analysis;World Journal of Gastroenterology;2024-01-28

2. Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study;Hepatology Research;2024-01-19

3. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE;Journal of Gastroenterology and Hepatology;2024-01-19

4. Chemotherapy‐Enabled Colorectal Cancer Immunotherapy of Self‐Delivery Nano‐PROTACs by Inhibiting Tumor Glycolysis and Avoiding Adaptive Immune Resistance;Advanced Science;2024-01-18

5. The Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Near-term Prognostic Indicator in Patients with Locally Advanced Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy: A Propensity Score Matching Cohort Study;2024-01-18